FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-03

Price

$14.34

-0.14%

Score6.8Priority

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

FOLD is currently a 'Special Situation' purely driven by Merger Arbitrage, not fundamental price discovery. The stock is pinned to the $14.50/share all-cash acquisition offer from BioMarin Pharmaceutical (BMRN), and today's price action reflects the successful Shareholder Approval of the merger (confirmed March 3, 2026). In a 'RISK_OFF' macro regime, FOLD's relative strength (+2.6% vs SPY) and low volatility (2.0%) confirm it is functioning as a capital preservation vehicle for institutional arbitrageurs harvesting the remaining ~1.1% spread.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Thesis: The trade is 'Arb & Hold'. The deal is effectively derisked by today's shareholder vote; the remaining $0.16 spread is the yield for waiting on final closing.
Signal Check: 'STEADY_CLIMB' and 'QUIET_STORM' are false positives for organic growth; they actually signal the mechanical peg to the $14.50 deal price.
Risk: Regulatory intervention (FTC) is the only remaining hurdle, though low probability given the sector dynamics.

← Back to 2026-03-03 View Full FOLD History →Yahoo Finance &nearr;